171sek
6,4 %
Date:2024-04-26Time:17:29:38Latest report:Q3-2024List:First NorthTicker:BIOVIC B
Market Cap:143 msekEnterprise Value:46 msekNet Sales:5,98 msekEarnings:-123,0 msekEmployees:0ISIN:SE0008613731

Ratios

10-year key figure history for Biovica turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Biovica with index and moving average MA50 and MA200.

Stockprice:1,71
MA50:2,28
MA200:4,25
Price/MA200:-59,9 %
RSI (14):30,6
Price/MA50:-25,2 %

Description

Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biotechnology